TORONTO, Dec. 21, 2017 /CNW/ - Strainprint™ – the leader in cannabis data collection and strain efficacy reporting – is excited to announce that 48North Cannabis (48North) has subscribed to Strainprint's world-leading cannabis data & analytics platform to help guide its operational growth and product development.
48North's Ontario-based cultivation facility Delshen Therapeutics is a Health Canada Licensed Producer with unique genetics sourced from the Netherlands' first cannabis license holder, MariPharm B.V. 48 North plans to use Strainprint's data and analytics tools to support the existing medical research on their proprietary strains and to develop cannabis products and brands that meet the needs of a variety of consumers.
"Strainprint's unique ACMPR strain efficacy and patient use data will help us to produce the highest quality products that will support our patients and recreational consumers in navigating their cannabis experiences.," said Alison Gordon, 48North CEO.
Thousands of ACMPR patients have tracked almost 150,000 medication sessions from our industry-leading mobile app generating over 4 million data points on strain efficacy and patient use. It is the largest and most granular longitudinal data set in the world on strain efficacy and patient use of lab-verified products. In addition to guiding patients, this data is helping to shape the entire cannabis industry by providing business intelligence for all stakeholders, including licensed producers, doctors and clinics, researchers, pharma and insurance providers.
"Our mission is to help our users and our subscriber customers to better understand how cannabis works and how it can best be used for whatever their purpose. We are ecstatic to be working with 48North to provide them with the most reliable source of data that will be instrumental for developing premium products for their consumers and patients," said Strainprint CEO, Andrew Muroff.
The Strainprint mobile App is free and is available for both iOS & Android from the Apple iTunes and Google Play Stores, respectively.
Founded in Toronto in 2016, Strainprint™ Technologies Ltd. is the leading demand-side cannabis data and analytics company, gathering real-time cannabis consumption and efficacy data on lab-verified strains, while providing enterprise business intelligence to the global cannabis industry. Strainprint™ data supports global cannabis research and provides advanced business intelligence to producers, retailers, medical practitioners, pharma, government and industry. Strainprint is HIPAA, PIPEDA and PHIPA privacy compliant, military-grade encrypted and all patient data is completely anonymized and at rest in Canada. Strainprint can be seamlessly embedded or integrated with most electronic medical records (EMR) and seed2sale software systems. The Strainprint App is free to patients and can be downloaded from both the iOS App Store and GooglePlay Store. www.strainprint.ca, facebook, twitter, linkedin
About 48 North:
48North is a vertically integrated cannabis company. Its first ACMPR licensed facility is located on 800 acres of owned land near Kirkland Lake, Ontario, and is operated by its wholly-owned subsidiary, DelShen Therapeutics. The company grows unique genetics sourced from MariPharm B.V., a Netherlands based phytopharmaceutical company with over 25 years of experience in the research and cultivation of cannabis for medical purposes. The genetics are grown to exacting standards in DelShen's state-of-the-art, closed box facility, ensuring patients can count on receiving the highest quality cannabis products. 48North's values are rooted in the land they're planted on, and the company has entered into a first of its kind Community Benefits Agreement with certain of its First Nations investors.
SOURCE Strainprint™ Technologies Ltd.
For further information: Media Contact: Jessica Moran, Strainprint™ Technologies Ltd., email@example.com, 519-494-5379